Other
Anti-CD19
0
Pipeline Programs↗
1
Active Trials↗
0
Companies Involved↗
Anti-CD19 is an early-stage landscape with 0 programs across 0 companies.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
3
clinical trials
Not yet recruiting1 · 33%
Unknown status1 · 33%
Withdrawn1 · 33%
Clinical Trials
Trial Activity
Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL
Unknown status·—·Phase 1/2·NCT05639179·30 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)